Skip to Main Content
Contribute Try STAT+ Today

The demise of IBM’s Watson Health would be easy to file away as another ill-fated attempt to tackle health care without understanding its complexities. But its downfall offers specific lessons on the implementation of artificial intelligence in an industry still clamoring for new ways to mine mountains of data.

One of IBM’s biggest mistakes, business analysts and informatics experts said, was picking overly ambitious targets — such as cancer treatment and drug discovery — but failing to engage deeply enough in the science to build products that would demonstrably improve outcomes.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.